Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 97 clinical trials
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

AIO-YMO/TRK-0416 (DURATION) is a open-label, treatment stratified and randomized phase II study of Durvalumab, frail or elderly patients with metastatic non-squamous NSCLC with no targetable

vinorelbine
solid tumour
gemcitabine
kidney function test
medi4736
  • 107 views
  • 29 Jan, 2021
  • 41 locations
  • 0 views
  • 19 Jun, 2021
  • 30 locations
Study of KN046 With Chemotherapy in First Line Advanced NSCLC

This is a phase II study of KN046 plus platinum-based doublet chemotherapy in previously untreated advanced non-squamous and squamous NSCLC subjects. The study will assess primarily the

  • 0 views
  • 23 Jan, 2021
  • 1 location
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

pemetrexed, cisplatin in approximately 228 TKI(tyrosine kinase inhibitor) pre treated patients with Stage IV non squamous non small cell lung cancer with activating EGFR mutation or ALK translocation.

egfr t790m
epidermal growth factor
pleural effusion
cancer chemotherapy
secondary malignant neoplasm of liver
  • 0 views
  • 01 Feb, 2021
  • 1 location
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer Urothelial Cancer and Malignant Mesothelioma

This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.

lung carcinoma
cancer chemotherapy
lung cancer
cabozantinib
pemetrexed
  • 0 views
  • 27 Jan, 2021
  • 1 location
PD-1 Inhibitors and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

NSCLC and 9.2 months in squamous NSCLC . In this setting the programmed death 1/ligand 1 (PD-1/-L1) were targeted with nivolumab (IgG4) in advanced squamous and nonsquamous NSCLC leading to an increase

nivolumab
cancer chemotherapy
secondary malignant neoplasm of liver
carboplatin
anticoagulants
  • 3 views
  • 25 Jan, 2021
  • 9 locations
Study of Crizotinib for ROS1 and MET Activated Lung Cancer

This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective …

ROS1
cancer
crizotinib
squamous non-small cell lung cancer
measurable disease
  • 0 views
  • 11 Apr, 2021
  • 1 location
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance

found in only the half of the non-squamous NSCLC . More recently, immune check point inhibitors (ICI), firstly targeting PD-(L)1, became available and demonstrate an overall survival advantage over

ROS1
serum bilirubin level
recurrent non-small cell lung cancer
medi4736
docetaxel
  • 0 views
  • 09 Apr, 2021
  • 1 location
Testing the Addition of the Pill Chemotherapy Cabozantinib to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

This phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung

step 2
ROS1
tumor cells
HIV Infection
chronic hepatitis b
  • 25 views
  • 20 Jun, 2021
  • 458 locations
NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

This is a multicenter screening protocol designed to identify patients with NSCLC who have tumor mutations in the KEAP1 or NRF2/NFE2L2 genes in order to determine potential eligibility for a biomarker selected clinical trial (CX-839-014, otherwise known as the KEAPSAKE trial). Circulating tumor DNA (ctDNA) present in blood samples collected …

  • 0 views
  • 05 Mar, 2021
  • 60 locations